9d9 antibody Search Results


vegfr3/flt-4 antibody (9d9) - azide and bsa free  (Bio-Techne corporation)
90
Bio-Techne corporation vegfr3/flt-4 antibody (9d9) - azide and bsa free
Vegfr3/Flt 4 Antibody (9d9) Azide And Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/9d9+antibody/bio-techne+corporation___nbp1-18651?v=Bio-Techne+corporation
Average 90 stars, based on 1 article reviews
vegfr3/flt-4 antibody (9d9) - azide and bsa free - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
gclc  (Novus Biologicals)
92
Novus Biologicals gclc
Gclc, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/9d9+antibody/pm29329420-35-40-43?v=Novus+Biologicals
Average 92 stars, based on 1 article reviews
gclc - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
checkpoint blockade antibodies directed against ctla4 clone 9d9  (Bioconnect Systems Inc)
90
Bioconnect Systems Inc checkpoint blockade antibodies directed against ctla4 clone 9d9
B16F10-OVA therapeutic vaccination comparing pTOP vaccines and classical DNA vaccination, and combination with immune checkpoint blockade. (A) Schematic protocol of the B16F10-OVA injection and therapeutic DNA vaccination. C57BL/6 mice were first injected with B16F10-OVA. The DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. (B) Tumor growth curves for the different groups. (C) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: one-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. *p<0.05, compared with naive or to the specified group. (D) schematic protocol of the B16F10-OVA injection, therapeutic DNA vaccination and immune checkpoint blockade administration. C57BL/6 mice were first injected with B16F10-OVA. the DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. Immune checkpoint blockade antibodies against <t>CTLA4</t> (100 µg) and PD1 (100 µg) were injected intraperitoneally 3, 6 and 9 days after tumor injection. (E) tumor growth curves for the different groups. (F) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. **p<0.01, compared with naive or to the specified group. ANOVA, analysis of variance; MST, median survival time; OVA, ovalbumin; pOVA, plasmid OVA; pTOP, plasmid to deliver T cell epitopes; pVSVG, plasmid vesicular stomatitis virus glycoprotein.
Checkpoint Blockade Antibodies Directed Against Ctla4 Clone 9d9, supplied by Bioconnect Systems Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/9d9+antibody/pmc08021892-62-6-17?v=Bioconnect+Systems+Inc
Average 90 stars, based on 1 article reviews
checkpoint blockade antibodies directed against ctla4 clone 9d9 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
vegfr3/flt-4 antibody (9d9) [alexa fluor® 488]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [Alexa Fluor® 488] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA,
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [alexa fluor® 647]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [Alexa Fluor® 647] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA,
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [janelia fluor® 646]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [Janelia Fluor® 646] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA,
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [mfluor violet 500 se]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [mFluor Violet 500 SE] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry,
   Buy from Supplier
ctla-4 antibody [9d9], rabbit igg  (ProSci Incorporated)
N/A
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [alexa fluor® 700]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [Alexa Fluor® 700] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA,
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [dylight 350]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [DyLight 350] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA, Immunohistochemistry,
   Buy from Supplier
vegfr3/flt-4 antibody (9d9) [dylight 550]  (Novus Biologicals)
N/A
The VEGFR3/Flt-4 Antibody (9D9) [DyLight 550] from Novus is a VEGFR3/Flt-4 antibody to VEGFR3/Flt-4. This antibody reacts with Human. The VEGFR3/Flt-4 antibody has been validated for the following applications: Western Blot, Flow Cytometry, ELISA, Immunohistochemistry,
   Buy from Supplier

Image Search Results


B16F10-OVA therapeutic vaccination comparing pTOP vaccines and classical DNA vaccination, and combination with immune checkpoint blockade. (A) Schematic protocol of the B16F10-OVA injection and therapeutic DNA vaccination. C57BL/6 mice were first injected with B16F10-OVA. The DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. (B) Tumor growth curves for the different groups. (C) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: one-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. *p<0.05, compared with naive or to the specified group. (D) schematic protocol of the B16F10-OVA injection, therapeutic DNA vaccination and immune checkpoint blockade administration. C57BL/6 mice were first injected with B16F10-OVA. the DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. Immune checkpoint blockade antibodies against CTLA4 (100 µg) and PD1 (100 µg) were injected intraperitoneally 3, 6 and 9 days after tumor injection. (E) tumor growth curves for the different groups. (F) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. **p<0.01, compared with naive or to the specified group. ANOVA, analysis of variance; MST, median survival time; OVA, ovalbumin; pOVA, plasmid OVA; pTOP, plasmid to deliver T cell epitopes; pVSVG, plasmid vesicular stomatitis virus glycoprotein.

Journal: Journal for Immunotherapy of Cancer

Article Title: New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models

doi: 10.1136/jitc-2020-001243

Figure Lengend Snippet: B16F10-OVA therapeutic vaccination comparing pTOP vaccines and classical DNA vaccination, and combination with immune checkpoint blockade. (A) Schematic protocol of the B16F10-OVA injection and therapeutic DNA vaccination. C57BL/6 mice were first injected with B16F10-OVA. The DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. (B) Tumor growth curves for the different groups. (C) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: one-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. *p<0.05, compared with naive or to the specified group. (D) schematic protocol of the B16F10-OVA injection, therapeutic DNA vaccination and immune checkpoint blockade administration. C57BL/6 mice were first injected with B16F10-OVA. the DNA vaccines were intramuscularly electroporated 2, 9 and 16 days after injection of the tumor cells. Immune checkpoint blockade antibodies against CTLA4 (100 µg) and PD1 (100 µg) were injected intraperitoneally 3, 6 and 9 days after tumor injection. (E) tumor growth curves for the different groups. (F) percentage of survival as a function of time. The error bars represent the mean±SEM; n=6. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons test, two-way ANOVA with Bonferroni post-tests or Mantel-Cox test for comparison of survival curves. **p<0.01, compared with naive or to the specified group. ANOVA, analysis of variance; MST, median survival time; OVA, ovalbumin; pOVA, plasmid OVA; pTOP, plasmid to deliver T cell epitopes; pVSVG, plasmid vesicular stomatitis virus glycoprotein.

Article Snippet: Immune checkpoint blockade antibodies directed against CTLA4 (clone 9D9) and PD1 (clone 29 F.A12) were purchased from Bioconnect (Netherlands) and mice were injected intraperitoneally with 100 μg of each antibody in 100 μl of PBS 3, 6 and 9 days after tumor injection.

Techniques: Vaccines, Injection, Comparison, Plasmid Preparation, Virus